Overview and History of NOLVAMED 20 (Tamoxifen
citrate)
NOLVAMED 20 (Tamoxifen
citrate) belongs to a class of drugs known as selective
Estrogen receptor modulators (called SERMs for short). Selective Estrogen
receptor modulators belong to an even broader category of drugs known as
anti-estrogens. The other subcategory of drug under the anti-estrogens category
is known as aromatase inhibitors (AIs), such as AROMAMED 25 (Exemestane) and ARIMIMED 1 (Anastrozole).
AIs and SERMs make up anti-estrogens,
also known as Estrogen antagonists or Estrogen blockers. Aromatase inhibitors are very different from SERMs
in their action and how they deal with the issues of Estrogen control. There
is a misconception among the anabolic steroid
using community that SERMs, such as NOLVAMED 20 (Tamoxifen
citrate) and CLOMIMED 50 (Clomiphene
citrate), serve to lower estrogen levels. That is not true. SERMs serve to block
the action of Estrogen at the receptor sites in breast tissue by occupying the
receptor sites in place of Estrogen so that Estrogen itself cannot exert its
effects there through receptor site binding. On the contrary, SERMs will also
act as Estrogens at receptor sites at other cells in other areas of the body
(for example the liver, like NOLVAMED 20 (Tamoxifen
citrate). SERMs do not lower circulating levels of Estrogen in blood plasma.
Aromatase inhibitors do this by eliminating the production of Estrogen through
binding to and disabling the aromatase enzyme, which is the enzyme responsible
for the conversion (or aromatization) of androgens into Estrogen.
NOLVAMED 20 (Tamoxifen
citrate) is specifically a non-steroidal SERM which is part
of the triphenylethylene family of compounds that exhibits both Estrogen
agonist and Estrogen antagonistic effects on the body. Although NOLVAMED 20 (Tamoxifen
citrate) might block the effect of Estrogen at the cellular
level in certain tissues, it can enhance Estrogenic effects in other areas of
the body. These effects can be both: positive and negative. NOLVAMED 20 (Tamoxifen
citrate) exhibits Estrogenic effects in the liver, which is
a positive effect, as it results in a positive change in cholesterol profiles. The area of
concern during the usage of NOLVAMED 20 (Tamoxifen
citrate) is breast tissue, where the drug
acts as a very strong anti-Estrogen. This is where it is utilized in the medical field, as a
first-line treatment in Estrogen-responsive female breast cancer patients. NOLVAMED 20 (Tamoxifen
citrate) is even utilized in females that do not possess breast cancer but are
known as being in a high-risk category (due to hereditary genetics or
otherwise) as a preventative measure.
NOLVAMED 20 (Tamoxifen
citrate) possesses other attractive effects, such as its ability to increase
circulating levels of endogenous gonadotropins Luteinizing Hormone (LH) and
Follicle Stimulating Hormone (FSH), and through this, increasing the endogenous
production of Testosterone. This is a great example of the mixed Estrogen
antagonistic and agonistic properties of NOLVAMED 20 (Tamoxifen
citrate), where it works to block the ability for Estrogen to bind to receptors
at the hypothalamus. Such actions result in the manipulation of the negative
feedback loop of the HPTA (Hypothalamic Pituitary Testicular Axis), and in the
increased output of gonadotropins (the hormones that signal the testes to begin
or increase the output of Testosterone production). Because of this reason NOLVAMED 20 (Tamoxifen
citrate) is considered an essential component of a PCT (Post
Cycle Therapy) cycle to restore the function of endogenous Testosterone
production.
Tamoxifen citrate was developed by ICI in 1962 and shortly afterward was released onto the prescription drug
market in the United States. The very first application of this compound in
medicine was the treatment of female infertility. Later, after various clinical
testing, NOLVAMED 20 (Tamoxifen
citrate) was found to be highly effective in the treatment
of breast cancer patients. Tamoxifen citrate has spread internationally.
Thousands of different brands and generics of it have been created.
Chemical Characteristics of NOLVAMED 20
(Tamoxifen citrate)
NOLVAMED 20 (Tamoxifen
citrate) is a non-steroidal selective Estrogen
receptor modulator (SERM) that possesses both mixed agonistic and antagonistic
properties concerning Estrogen in different areas of the body. NOLVAMED 20 (Tamoxifen
citrate) is part of the family of compounds known as triphenylethylene compounds.
CLOMIMED 50 (Clomiphene
citrate) is also a member of this family and a very closely related compound to NOLVAMED 20 (Tamoxifen
citrate).
Properties of NOLVAMED 20 (Tamoxifen citrate)
Being a SERM, NOLVAMED 20 (Tamoxifen
citrate) does not reduce circulating Estrogen levels in the
body but instead serves to occupy the receptor sites in breast tissue so that
Estrogen itself cannot bind to these receptors due to NOLVAMED 20 (Tamoxifen
citrate) stronger binding strength to it. NOLVAMED 20 (Tamoxifen
citrate) acts as a ‘fake’ Estrogen that acts as a
placeholder at the receptor sites in breast tissue. As a result, Estrogen
cannot activate gene transcription in the cells there to formulate
gynecomastia, and any existing Estrogen that has already bound to receptor
sites will essentially be ‘forced’ out of the receptor sites by NOLVAMED 20 (Tamoxifen
citrate) which then occupies the receptor site instead. This
quality is perfect for anabolic steroid users that wish to eliminate and
reverse formulating gynecomastia in its early stages, as well as for those
users which are very sensitive to the gynecomastia side effect of rising
Estrogen levels that might wish to use NOLVAMED 20 (Tamoxifen
citrate) as a preventative measure. This is the primary
function of NOLVAMED 20 (Tamoxifen
citrate) and is the main desired effect that anabolic
steroid using bodybuilders and athletes utilize it for.
NOLVAMED 20 (Tamoxifen
citrate) will not serve
to block or reduce any other Estrogenic side effects, as it serves only to
block Estrogenic activity at the breast tissue area (when major Estrogenic side
effects are concerned). The same like any other SERMs, NOLVAMED 20 (Tamoxifen
citrate) does not serve
to reduce bloating, water retention, rising blood pressure (as a result of
water retention), or acne formation – these are all side effects resultant from
increasing blood plasma Estrogen levels.
NOLVAMED 20 (Tamoxifen citrate) Side Effects
NOLVAMED 20 (Tamoxifen
citrate) is a compound that is tolerated quite well by the
majority of users. Like with any other compound, there are some potential side effects
to be aware of. Because of the difference in androgen and Estrogen receptor
proliferation among cells in the male and female bodies, NOLVAMED 20 (Tamoxifen
citrate) can generate quite different effects depending on
the gender of the user. This is the reason why there are many negative
experiences with NOLVAMED 20 (Tamoxifen
citrate) side effects among female users. Anyway, this is a different story in comparison to
its use among bodybuilders and athletes using NOLVAMED 20 (Tamoxifen
citrate) as an ancillary compound surrounding their anabolic
steroid use.
The official prescription documentation for NOLVAMED 20 (Tamoxifen
citrate) side effects when it is used as a female breast
cancer treatment drug includes hot flashes, vaginal itching, upset stomach,
headaches, dizziness, bone and joint pains, and edema. Less common side effects
may include cholesterol changes, altered white blood cell count, altered
platelet count, skin rashes, endometrial changes, deep vein thrombosis, and
pulmonary embolism. The mentioned NOLVAMED 20 (Tamoxifen
citrate) side effects are practically a non-concern for male
users, as the overwhelming majority of said side effects are reportedly seldom
experienced among men users.
Dosages and Administration of NOLVAMED 20
(Tamoxifen citrate)
In the medical field, NOLVAMED 20 (Tamoxifen
citrate) is used as a medication in the treatment of 6 different
types of female breast cancer. The
prescription dosing and administration of NOLVAMED 20 (Tamoxifen
citrate) in these cases call for 10 – 20mg taken twice per
day, in the morning and evening respectively.
Within the bodybuilding and performance
enhancement world, NOLVAMED 20 (Tamoxifen
citrate) is primarily used as an ancillary aid to combating,
reducing, and/or preventing the development of Gynecomastia. This usually
happens when a particularly moderate or aromatizable anabolic steroid is
utilized in a cycle. Dosing of NOLVAMED 20 (Tamoxifen
citrate) in this case is approximately 10 – 30mg per day.
The common dosing tends to be 20mg per day of NOLVAMED 20 (Tamoxifen
citrate). That
must be noted, that higher dosages of NOLVAMED 20 (Tamoxifen
citrate), greater than 20 – 40mg per day, does not produce any greater or faster
effect on reducing or preventing gynecomastia.
The other purpose for NOLVAMED 20 (Tamoxifen
citrate) use among bodybuilders and athletes is its ability to
stimulate and increase the male production of endogenous Testosterone, as many
studies have shown. It does so by acting on the pituitary and hypothalamus
gland in the brain and signaling an increase in production of FSH (Follicle
Stimulating Hormone) and LH (Luteinizing Hormone), which then signals the
testes to produce Testosterone. NOLVAMED 20 (Tamoxifen
citrate) is usually administered during PCT, which is
immediately after the anabolic steroid cycle is complete and all anabolic
steroids are clear from the individual’s system. The dosage is 20 – 40mg
per day, the cycle length of approximately 4 – 6 weeks. Studies have shown that venturing higher than 20 – 40mg per day does not
generate any significantly greater amount of Testosterone production.
NOLVAMED 20 (Tamoxifen
citrate) is usually included with the administration of at
least one or two other Testosterone stimulating compounds during PCT (such as
an aromatase inhibitor, usually AROMAMED 25 (Exemestane), and/or HCG) to enhance its effects on
promoting proper HPTA function following the conclusion of a cycle. The utilization of NOLVAMED 20 (Tamoxifen
citrate) during a cycle will not counter-act the
Testosterone suppression of anabolic steroid use and will not keep endogenous
Testosterone production going amidst the use of suppressive compounds. It is
therefore not recommended to do that, as it would be useless. NOLVAMED 20 (Tamoxifen
citrate) possesses an extremely long half-life for an oral
compound, approximately 5 – 7 days. Some studies even demonstrated a longer
half-life of 14 days. Because of this, there is no requirement to split dosages
throughout the day. It is safe to consume NOLVAMED 20 (Tamoxifen
citrate) together with food or on an empty stomach.
Chemical info /
Information
Tamoxifen
Citrate (AKA Nolvadex)
Chemical Name: (Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine
Molecular Weight: 371.515 g/mol or 563.638 g/mol (citrate salt)
Formula: C26H29NO
Original Manufacturer: ICI
Elimination half-life: 5 – 7 days (some reports as long as 14 days)
Detection Time: 2 months
Anabolic Rating: N/A
Androgenic Rating: N/A
Related Products
